FCGR2A and nonpapillary renal cell carcinoma: Our study establishes FCGR2A as a pivotal interface between metabolic inflammation and ccRCC progression, reconciling the paradoxical association of obesity with both increased cancer risk and enhanced immunotherapy responses (8).